UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers.
Data-focused CRO Quanticate (Hitchin, UK) will partner with cancer research organisation Cancer Research UK to support the launch of their DETERMINE study, testing a range of therapies targeting key genetic mutations in cancer cells, a first of its kind in the UK.
The DETERMINE study will focus on patients with rare cancers in order to investigate the utilisation of existing licensed drugs for the treatment of particular rare cancers. Individuals with an identifiable genetic alteration in their cancer will form cohorts to be targeted by treatments already approved for other cancer types. As a data-focused CRO with a primary focus on data capture, statistical analysis, and clinical trial report, Quanticate will work with Cancer Research UK’s Centre for Drug Development to ensure the optimisation of the study’s statistical design.
Commenting on Quanticate’s role in the DETERMINE study, CEO David Underwood stated: “The study will strive to improve the outcome for patients who may have run out of options during their cancer journey... Cancer Research UK has asked adults, young people, and children who are suffering with a rare type of cancer to come forward with the possibility that there may be an existing approved drug that could benefit them. Furthermore, analyss from this study could also open up successful treatment options for other patients with similar cancer types who are not enrolled on the trial.” The study is slated to commence across the UK from September 2022, with approximately 15–20 treatment branches each with initial trial cohorts of 30 evaluable patients.
Underwood further commented: “Quanticate is delighted to partner with Cancer Research UK for a program so close to home for many people and we are hopeful that the study will be successful in finding results that will improve the quality of life for many patients.”
Nigel Blackburn, Director of Cancer Research UK’s Centre for Drug Development, added, “We’re delighted to partner with Quanticate and welcome the valuable expertise they bring to this incredibly important trial which will allow potentially life-saving treatments to be opened up to people with rare cancers.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance